[Alpha Tau in PR Newswire] Alpha Tau announces enrollment of first patient in combination trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has enrolled its first patient in the combination study of Alpha DaRT and pembrolizumab (Keytruda®) at Hadassah Medical Center in Jerusalem, Israel. Read more...
Read More